• Evolus entered an option agreement with a privately held developer of a sustained-release injectable hair restoration treatment.
• Initial option payment totals $1.5 million, with additional stage-gated payments tied to development milestones.
• Evolus will support development work, including an initial clinical proof-of-concept study.
• Deal grants an option to acquire 100% of program assets following an initial clinical dataset.
• Formulation work is expected through 2027; first-in-human studies are anticipated to start afterward.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610140830BIZWIRE_USPR_____20261014_BW335989) on October 14, 2026, and is solely responsible for the information contained therein.